Literature DB >> 5925444

Hydroxyproline excretion in malignant neoplastic disease.

H F Hosley, E G Taft, K B Olson, S Gates, R T Beebe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5925444

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  9 in total

1.  Urinary hydroxyproline in the management of breast cancer.

Authors:  A Cuschieri
Journal:  World J Surg       Date:  1977-05       Impact factor: 3.352

2.  Urinary hydroxyproline excretion in carcinoma of the breast.

Authors:  A Cuschieri; R A Felgate
Journal:  Br J Exp Pathol       Date:  1972-06

3.  Urinary total hydroxyproline: creatinine ratio. Range of normal, and clinical application in British children.

Authors:  B A Wharton; G Gough; A Williams; S Kitts; C A Pennock
Journal:  Arch Dis Child       Date:  1972-02       Impact factor: 3.791

4.  Urinary excretion of prolylhydroxyproline in rheumatic diseases.

Authors:  A C Bienenstock HKIBRICK
Journal:  Ann Rheum Dis       Date:  1969-01       Impact factor: 19.103

5.  [The behavior of the "collagen-like protein" in serum of patients with seleroderma before and following treatment with gestagens].

Authors:  H Holzmann; G W Korting; B Morsches; A Schlaudecker
Journal:  Arch Klin Exp Dermatol       Date:  1967

6.  Urinary excretion of glycosaminoglycans in disseminated neoplasm.

Authors:  G Manley; L Bower; A Anson
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

7.  Urinary hydroxyproline levels in patients with prostatic carcinoma.

Authors:  D Erol; N Adalar; S Güvençli; F Simşek
Journal:  Int Urol Nephrol       Date:  1983       Impact factor: 2.370

8.  Free serum hydroxyproline and total urinary hydroxyproline for the detection of skeletal metastasis.

Authors:  A B Gasser; D Depierre; B Mermillod; B Courvoisier
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

9.  Relevance of hydroxyproline excretion to bone metastasis in breast cancer.

Authors:  F Gielen; J Dequeker; A Drochmans; J Wildiers; M Merlevede
Journal:  Br J Cancer       Date:  1976-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.